Document Detail


A retrospective study of skeletal and disease-free survival benefits of zoledronic acid therapy in patients with multiple myeloma treated with novel agents.
MedLine Citation:
PMID:  23236556     Owner:  NLM     Status:  PubMed-not-MEDLINE    
Abstract/OtherAbstract:
BACKGROUND: The large majority of patients with multiple myeloma develop bone lesions and typically receive bisphosphonates to maintain bone health and prevent/delay skeletal-related events. Recent clinical data show that the newer-generation bisphosphonate, zoledronic acid, may confer a survival benefit when combined with antimyeloma therapy. However, clinical data describing the combination of zoledronic acid with newer antimyeloma regimens are limited.
DESIGN AND METHODS: This retrospective study analyzed efficacy and safety outcomes in patients with multiple myeloma receiving first- and second-line treatment with bortezomib, lenalidomide, or thalidomide, with or without zoledronic acid.
RESULTS: Records data from 94 patients with Durie-Salmon stage 3A/B multiple myeloma were collated. Most patients (~80%) had bone lesions at study entry. Almost all patients received zoledronic acid at some time during their treatment. Adding zoledronic acid was associated with a numerical, but statistically nonsignificant, benefit in the 1-year progression-free survival rate in both the first- and second-line setting. A similar benefit was observed on the 2-year skeletal-related event rate. Notably, combining zoledronic acid with newer antimyeloma agents was feasible, tolerable, and did not affect the duration of antimyeloma treatment. Three cases of osteonecrosis of the jaw were reported; there were no reports of acute renal failure.
CONCLUSIONS: This retrospective analysis suggests that extended treatment with zoledronic acid in combination with bortezomib, lenalidomide, or thalidomide is safe and tolerable in patients receiving these therapies as first- or second-line treatment. The addition of zoledronic acid may improve both myeloma and skeletal-related outcomes.
Authors:
Roberto Ria; Antonia Reale; Michele Moschetta; Giuseppe Mangialardi; Franco Dammacco; Angelo Vacca
Related Documents :
20405916 - Formation of volatile chemicals from thermal degradation of less volatile coffee compon...
1487326 - Trans,trans-muconic acid, a reliable biological indicator for the detection of individu...
12517116 - Antioxidant constituents of almond [prunus dulcis (mill.) d.a. webb] hulls.
20199996 - The phytochemical composition and antioxidant actions of tree nuts.
20007686 - L-glutamine inhibits beta-aminobutyric acid-induced stress resistance and priming in ar...
44796 - Ph-map of the stomach of normal and vagotomized dogs.
Publication Detail:
Type:  Journal Article     Date:  2012-11-18
Journal Detail:
Title:  International journal of clinical and experimental medicine     Volume:  6     ISSN:  1940-5901     ISO Abbreviation:  Int J Clin Exp Med     Publication Date:  2013  
Date Detail:
Created Date:  2012-12-13     Completed Date:  2012-12-14     Revised Date:  2013-05-30    
Medline Journal Info:
Nlm Unique ID:  101471010     Medline TA:  Int J Clin Exp Med     Country:  United States    
Other Details:
Languages:  eng     Pagination:  30-8     Citation Subset:  -    
Affiliation:
Department of Biomedical Sciences and Human Oncology, Section of Internal Medicine and Clinical Oncology, University of Bari Medical School Bari, Italy.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Hemodynamic changes following the administration of propofol to facilitate endotracheal intubation d...
Next Document:  Association of estrogen receptor-? A908G (K303R) mutation with breast cancer risk.